ORIGINAL ARTICLE: EPIDEMIOLOGY, CLINICAL PRACTICE AND HEALTH

Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction

Nozomi Hishikawa

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Yusuke Fukui,

Yusuke Fukui

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Kota Sato,

Kota Sato

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Yasuyuki Ohta,

Yasuyuki Ohta

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Toru Yamashita,

Toru Yamashita

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Koji Abe,

Corresponding Author

Koji Abe

[email protected]

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Correspondence: Professor Koji Abe MD PhD, Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikatacho Kitaku, Okayama 700-8558, Japan. Email: [email protected]Search for more papers by this author

Nozomi Hishikawa,

Nozomi Hishikawa

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Yusuke Fukui,

Yusuke Fukui

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Kota Sato,

Kota Sato

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Yasuyuki Ohta,

Yasuyuki Ohta

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Toru Yamashita,

Toru Yamashita

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Search for more papers by this author

Koji Abe,

Corresponding Author

Koji Abe

[email protected]

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

First published: 31 August 2016

https://doi.org/10.1111/ggi.12870

Citations: 13

Share a link

Email
Wechat
Bluesky

Abstract

Aim

The coexistence of Alzheimer's disease (AD) and cerebrovascular disease pathology increases age-dependently. We comprehensively analyzed the clinical effects of galantamine or cilostazol monotherapy to the add-on combination therapy on three major factors of dementia, such as cognitive, affective and activities of daily living functions in AD patients with asymptomatic lacunar infarction.

Methods

We divided 101 AD patients with asymptomatic lacunar infarction into two subgroups: group A (n = 61, first treated with galantamine and then cilostazol added) and group B (n = 40, first treated with cilostazol and galantamine added). We compared the clinical effects before and after combination therapy of galantamine and cilostazol (i.e. 3 months [M] before (–3 M), baseline (0 M), 3 and 6 M after the add-on combination).

Results

Galantamine monotherapy increased cognitive Hasegawa dementia score-revised scores, which were further improved with add-on cilostazol. Cilostazol monotherapy also increased the cognitive tests, which were further improved with add-on galantamine. Add-on cilostazol significantly improved Geriatric Depression Scale and Abe's behavioral and psychological symptoms of dementia scores after galantamine monotherapy. Cilostazol monotherapy also significantly improved Geriatric Depression Scale scores, with further improvements in Geriatric Depression Scale, apathy scores and Abe's behavioral and psychological symptoms of dementia scores by add-on galantamine. Activities of daily living scores continuously improved with galantamine monotherapy and add-on cilostazol.

Conclusions

The present study provides a clinical possibility that galantamine or cilostazol monotherapy and the combination therapy maintained or even improved cognitive, affective, and activities of daily living functions in AD with asymptomatic lacunar infarction. Geriatr Gerontol Int 2017; 17: 1384–1391.

References

1Kivipelto M, Ngandu T, Fratiglioni L et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556–1560.
10.1001/archneur.62.10.1556
PubMed Web of Science® Google Scholar
2Raffaitin C, Gin H, Empana JP et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009; 32: 169–174.
10.2337/dc08-0272
PubMed Web of Science® Google Scholar
3Vanhanen M, Koivisto K, Moilanen L et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67: 843–847.
10.1212/01.wnl.0000234037.91185.99
CAS PubMed Web of Science® Google Scholar
4Tokuchi R, Hishikawa N, Kurata T et al. Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer's disease and reverting to normal cognition. J Neurol Sci 2014; 346: 288–292.
10.1016/j.jns.2014.09.012
PubMed Web of Science® Google Scholar
5Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 2010; 119: 421–433.
10.1007/s00401-010-0654-5
PubMed Web of Science® Google Scholar
6De la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 1993; 15: 146–153.
10.1080/01616412.1993.11740127
CAS PubMed Web of Science® Google Scholar
7Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004; 43: 605–608.
10.1016/S0896-6273(04)00533-1
CAS PubMed Web of Science® Google Scholar
8Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 2002; 300: 787–793.
10.1124/jpet.300.3.787
CAS PubMed Web of Science® Google Scholar
9Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 2006; 37: 1539–1545.
10.1161/01.STR.0000221783.08037.a9
CAS PubMed Web of Science® Google Scholar
10Sakurai H, Hanyu H, Sato T et al. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int 2013; 13: 90–97.
10.1111/j.1447-0594.2012.00866.x
PubMed Web of Science® Google Scholar
11Taguchi A, Takata Y, Ihara M et al. Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis. Psychogeriatrics 2013; 13: 164–169.
10.1111/psyg.12021
PubMed Web of Science® Google Scholar
12Omote Y, Deguchi K, Tian F et al. Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol. Stroke 2012; 43: 1639–1646.
10.1161/STROKEAHA.111.643098
CAS PubMed Web of Science® Google Scholar
13Ihara M, Nishino M, Taguchi A et al. Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. PLoS One 2014; 26: e89516.
10.1371/journal.pone.0089516
Web of Science® Google Scholar
14Arai H, Takahashi T. A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am J Geriatr Psychiatry 2009; 17: 353–354.
10.1097/JGP.0b013e31819431ea
PubMed Web of Science® Google Scholar
15McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939–944.
10.1212/WNL.34.7.939
CAS PubMed Web of Science® Google Scholar
16 Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990; 21: 637–676.
10.1161/01.STR.21.4.637
PubMed Web of Science® Google Scholar
17Abe K, Yamashita T, Hishikawa N et al. A new simple score (ABS) for assessing behavioral and psychological symptoms of dementia. J Neurol Sci 2015; 350: 14–17.
10.1016/j.jns.2015.01.029
CAS PubMed Web of Science® Google Scholar
18Fazekas F, Kleinert R, Offenbacher H et al. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. AJNR Am J Neuroradiol 1991; 12: 915–921.
CAS PubMed Web of Science® Google Scholar
19Hirata Y, Matsuda H, Nemoto K et al. Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 2005; 382: 269–274.
10.1016/j.neulet.2005.03.038
CAS PubMed Web of Science® Google Scholar
20Park SH, Kim JH, Bae SS et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation. Biochem Biophys Res Commun 2011; 408: 602–608.
10.1016/j.bbrc.2011.04.068
CAS PubMed Web of Science® Google Scholar
21Zhao J, Harada N, Kurihara H, Nakagata N, Okajima K. Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. Neuropharmacology 2010; 58: 774–783.
10.1016/j.neuropharm.2009.12.008
CAS PubMed Web of Science® Google Scholar
22Erkinjuntti T, Gauthier S, Bullock R et al. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). J Psychopharmacol 2008; 22: 761–768.
10.1177/0269881107083028
CAS PubMed Web of Science® Google Scholar
23Bär KJ, Boettger MK, Seidler N, Mentzel HJ, Terborg C, Sauer H. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. Stroke 2007; 38: 3186–3192.
10.1161/STROKEAHA.107.492033
CAS PubMed Web of Science® Google Scholar
24Shimizu S, Kanetaka H, Hirose D, Sakurai H, Hanyu H. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. Dement Geriatr Cogn Dis Extra 2015; 5: 135–146.
10.1159/000375527
PubMed Web of Science® Google Scholar
25Wu Z, Zhao L, Chen X, Cheng X, Zhang Y. Galantamine attenuates amyloid-β deposition and astrocyte activation in APP/PS1 transgenic mice. Exp Gerontol 2015; 72: 244–250.
10.1016/j.exger.2015.10.015
CAS PubMed Web of Science® Google Scholar
26Hishikawa N, Fukui Y, Sato K et al. Characteristic features of cognitive, affective and daily living functions of late-elderly dementia. Geriatr Gerontol Int 2016; 16: 458–465.
10.1111/ggi.12492
PubMed Web of Science® Google Scholar
27Nishimura K, Ishigooka J, Imamura Y, Ihara S. Cilostazol, a cAMP phosphodiesterase 3 inhibitor, in the treatment of poststroke depression. J Neuropsychiatry Clin Neurosci 2007; 19: 471–472.
10.1176/jnp.2007.19.4.471
PubMed Web of Science® Google Scholar
28Nakano Y, Matsuzono K, Yamashita T et al. Long-Term Efficacy of Galantamine in Alzheimer's Disease: The Okayama Galantamine Study (OGS). J Alzheimers Dis 2015; 47: 609–617.
10.3233/JAD-150308
CAS PubMed Web of Science® Google Scholar
29Hishikawa N, Fukui Y, Sato K et al. Cognitive and affective functions in Alzheimer's disease patients with metabolic syndrome. Eur J Neurol 2016; 23: 339–345.
10.1111/ene.12845
CAS PubMed Web of Science® Google Scholar
30Nagy Z, Esiri MM, Jobst KA et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 165–170.
10.1097/00005072-199702000-00007
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume17, Issue10

October 2017

Pages 1384-1391

Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction

Abstract

Aim

Methods

Results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction

Abstract

Aim

Methods

Results

Conclusions

References

Citing Literature

References

Related

Information